{"id":615,"date":"2019-07-31T00:11:06","date_gmt":"2019-07-31T04:11:06","guid":{"rendered":"https:\/\/sites.bu.edu\/hiv\/?page_id=615"},"modified":"2022-12-01T13:54:33","modified_gmt":"2022-12-01T18:54:33","slug":"resource-allocation-and-budget-impact","status":"publish","type":"page","link":"https:\/\/sites.bu.edu\/hiv\/economics\/resource-allocation-and-budget-impact\/","title":{"rendered":"Costs, resource allocation, and budget impact"},"content":{"rendered":"<ul class=\"display-posts-listing\"><li class=\"listing-item\"><a class=\"title\" href=\"https:\/\/sites.bu.edu\/hiv\/economics\/resource-allocation-and-budget-impact\/national-art-cost-model\/\">National ART Cost Model<\/a><\/li><li class=\"listing-item\"><a class=\"title\" href=\"https:\/\/sites.bu.edu\/hiv\/economics\/resource-allocation-and-budget-impact\/south-african-hiv-investment-case\/\">South African HIV Investment Case<\/a><\/li><\/ul>\n<h3>Other publications<\/h3>\n<div class=\"page\" title=\"Page 2\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 1\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><span>Jamieson L, Johnson L, Nichols BE, Delaney-Moretlwe S, Hosseinipour MC, Russell C, Meyer-Rath G. <a href=\"https:\/\/doi.org\/10.1016\/S2352-3018(22)00251-X\">Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis<\/a>. Lancet HIV 2022; https:\/\/doi.org\/10.1016\/S2352-3018(22)00251-X.\u00a0<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p><span>Bershteyn A, Jamieson L, Kim HY, Platais I, Milali MP, Mudimu E, Ten Brink D, Martin-Hughes R, Kelly SL, Phillips AN, Bansi-Matharu L, Cambiano V, Revill P, Meyer-Rath G, Nichols BE. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35961353\/\">Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models<\/a>. Lancet Glob Health. 2022 Sep;10(9):e1298-e1306. doi: 10.1016\/S2214-109X(22)00310-2. PMID: 35961353.<\/span><\/p>\n<p><span>Larson B, Shroufi A, Muthoga C <\/span><span>et al. <\/span><span><a href=\"https:\/\/wellcomeopenresearch.org\/articles\/6-140\/v3\">Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs<\/a>. <\/span><span>Wellcome Open Research 2022, <\/span><span>6<\/span><span>:140 <\/span><span>https:\/\/doi.org\/10.12688\/wellcomeopenres.16776.3 <\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>Long L, Rosen S, Nichols B, Larson B, Ndlovu N, Meyer-Rath G. <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.25707\">Getting resources to those who need them: evidence needed to budget for underserved populations carrying a disproportionate HIV burden in sub-Saharan Africa<\/a>.<em> J Int AIDS<\/em> Soc 2021; 24 (Suppl 3): e25707. PMID: 34189873<\/p>\n<p><span>Murphy JP, Kgowedi S, Naidoo N, Girdwood S, Jamieson L, Soeteman D, Resch S, Meyer-Rath G. <a href=\"https:\/\/pubmed-ncbi-nlm-nih-gov.ezproxy.bu.edu\/34212192\/\">Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual\/reproductive health programmes in South Africa<\/a>. <\/span><span>Health Policy Plan 2021; online ahead of print.<\/span><\/p>\n<p>Dickerson S, Baranov V, Bor J, Barofsky J. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32433760\/\">Treatment as insurance: HIV antiretroviral therapy offers financial risk protection in Malawi<\/a>. Health Policy Plan 2020; <span class=\"cit\">35:676-683.<\/span><\/p>\n<div class=\"page\" title=\"Page 1\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><span>Phillips AN, Cambiano V, Johnson L, Nakagawa F, Homan R, <em>Meyer-Rath G<\/em>, et al. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31851759-potential-impact-and-cost-effectiveness-of-condomless-sex-concentrated-prep-in-kwazulu-natal-accounting-for-drug-resistance\/\">Potential impact and cost-effectiveness of condomless-sex-concentrated PrEP in KwaZulu-Natal accounting for drug resistance<\/a>. J Infect Dis 2019.<\/span><span><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Other publications Jamieson L, Johnson L, Nichols BE, Delaney-Moretlwe S, Hosseinipour MC, Russell C, Meyer-Rath G. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV 2022; https:\/\/doi.org\/10.1016\/S2352-3018(22)00251-X.\u00a0 Bershteyn A, Jamieson L, Kim HY, [&hellip;]<\/p>\n","protected":false},"author":16424,"featured_media":0,"parent":25,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/sites.bu.edu\/hiv\/wp-json\/wp\/v2\/pages\/615"}],"collection":[{"href":"https:\/\/sites.bu.edu\/hiv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sites.bu.edu\/hiv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sites.bu.edu\/hiv\/wp-json\/wp\/v2\/users\/16424"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.bu.edu\/hiv\/wp-json\/wp\/v2\/comments?post=615"}],"version-history":[{"count":20,"href":"https:\/\/sites.bu.edu\/hiv\/wp-json\/wp\/v2\/pages\/615\/revisions"}],"predecessor-version":[{"id":1619,"href":"https:\/\/sites.bu.edu\/hiv\/wp-json\/wp\/v2\/pages\/615\/revisions\/1619"}],"up":[{"embeddable":true,"href":"https:\/\/sites.bu.edu\/hiv\/wp-json\/wp\/v2\/pages\/25"}],"wp:attachment":[{"href":"https:\/\/sites.bu.edu\/hiv\/wp-json\/wp\/v2\/media?parent=615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}